Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean 136 4s 3?
Displaying drugs 8251 - 8275 of 12008 in total

Surzebiclimab

Surzebiclimab is under investigation in clinical trial NCT03744468 (Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors).
Investigational

Tonabacase

Investigational

5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine

Experimental
Matched Name: … 5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine …
Matched Iupac: … 5-(4-methoxyphenoxy)quinazoline-2,4-diamine …

Lithium succinate

Experimental

N4-Hydroxycytidine

N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activity against Venezuelan equine encephalitis virus, and the human coronavirus HCoV-NL63 in vitro. N4-hydroxycytodine has been...
Experimental
Matched Synonyms: … 4-N-Hydroxycytidine ... Uridine, 4-oxime ... N(4)-Hydroxycytidine …
Matched Iupac: … 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)-1,2-dihydropyrimidin-2- …

Yttrium Y-90 clivatuzumab tetraxetan

Yttrium Y-90 clivatuzumab tetraxetan is under investigation in clinical trial NCT00603863 (Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer).
Investigational

(S)-wiskostatin

Experimental
Matched Name: … (S)-wiskostatin …
Matched Iupac: … (2S)-1-(3,6-dibromo-9H-carbazol-9-yl)-3-(dimethylamino)propan-2-ol …

SC12267

SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important...
Investigational

Nelipepimut-S

Investigational
Matched Synonyms: … Nelipepimut S ... Nelipepimut-S …
Matched Name: … Nelipepimut-S …

Sonepcizumab

A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).
Investigational

Sibrotuzumab

Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.
Investigational

Sarafloxacin

Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Vet approved
Withdrawn
Matched Iupac: … 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid …

Sapanisertib

Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.
Investigational
Matched Iupac: … 5-[4-amino-1-(propan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-1,3-benzoxazol-2-amine …

Sarpogrelate

Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.
Investigational
Matched Iupac: … 4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid …

Selurampanel

Selurampanel has been investigated in Adrenocortical Adenoma and Sarcoma, Endometrial Stromal.
Investigational
Matched Iupac: … N-[6-(1-methyl-1H-pyrazol-5-yl)-2,4-dioxo-7-(propan-2-yl)-1,2,3,4-tetrahydroquinazolin-3-yl]methanesulfonamide …

Sotrastaurin

Sotrastaurin has been used in trials studying the basic science and treatment of Uveal Melanoma, Richter Syndrome, Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, and Recurrent Small Lymphocytic Lymphoma, among others.
Investigational
Matched Iupac: … 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]-2,5-dihydro-1H-pyrrole-2,5-dione …

Sitafloxacin

Experimental
Investigational
Matched Iupac: … -1,4-dihydroquinoline-3-carboxylic acid) trihydrate ... bis(7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo …

Sitravatinib

Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).
Investigational
Matched Iupac: … N'1-(3-fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl ... )-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide …

Suvratoxumab

Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
Investigational

Sulfametrole

Experimental
Matched Iupac: … 4-amino-N-(4-methoxy-1,2,5-thiadiazol-3-yl)benzene-1-sulfonamide …

SYNB1891

SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult...
Investigational

SYNB1020

SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational

SHR-A1904

SHR-A1904 is under investigation in clinical trial NCT04877717 (A Study of SHR-A1904 in Patients With Advanced Solid Cancer).
Investigational

Larcaviximab

Investigational

(R,R)-2,3-Butanediol

Experimental
Displaying drugs 8251 - 8275 of 12008 in total